CRS in phase 2 trial
In the global trial ELIANA, CRS occurring in 50 of 65 patients (77%).
Fifty-three percent of patients experienced hypotension that required
intervention, and 24% required high-dose vasopressors. Fifteen percent
of patient were intubated, and 10% of patients required dialysis.
Thirty-nine percent of patients received tocilizumab. and 20% received
corticosteroids. All cases of CRS were reversible22.
Baseline disease burden, as defined by the percentage of blast cells in
bone marrow before infusion, correlated with the severity of CRS.
Patients with severe CRS also had higher levels of CAR positive CD8 and
CD3 positive cells.